Global Hepatitis C Drugs Market, by Drug Type (Interferon Based Therapies, NS5A Inhibitors, NS5B Inhibitors, and Protease Inhibitors), by Distribution Channel (Hospital Pharmacies,  Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$  7,376.6  million in 2019 and is expected to exhibit a CAGR of 4.0% over the forecast period (2019-2027), as highlighted in a new report published by Coherent Market Insights.

Hepatitis C is a major liver disease, and it has become a global burden. Moreover, key players are focused on developing new drugs for the treatment of hepatitis C. Increasing launches of new drugs is expected to drive the hepatitis C drugs market growth. For instance, in 2019, The AbbVie Inc. company received the U.S. Food and Drug Administration approval for Mavyret (glecaprevir and pibrentasvir) tablets to treat all six genotypes of hepatitis C virus (HCV) in children of age group of 12 to 17.

Moreover, in 2018, Nacto Pharma ltd launched a drug with brand name as Hepcinat Plus for the treatment of hepatitis C disease. This drug is generic form and fixed combination of Sofosbuvir-Declatasvir tablet. The company launched this drug at a retail price of US$ 246.1 for 28 tablets.

Furthermore, in 2018, Gilead Sciences Company launched generic versions of Harvoni and Epclusa, which was valued at US$ 24,000 for full course of therapy. The launch of these drugs helped to resolve the issue related to high cost of branded drugs, which is around US$ 100,000 for full course of therapy.

Browse 26 Market Data Tables and 27 Figures spread through 151 Pages and in-depth TOC on "Global Hepatitis C Drugs Market, by Drug Type (Interferon Based Therapies, NS5A Inhibitors, NS5B Inhibitors, and Protease Inhibitors), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2027"

To know the latest trends and insights related to global Hepatitis C Drugs market, click the link below:

https://www.coherentmarketinsights.com/market-insight/hepatitis-c-drugs-market-1489

Moreover, in 2016, Organisation for Economic Co-operation and Development performed an economic analysis in Australia used a mathematical model, which was based on the WHO strategy’s targets. On the basis of the results of this analysis, in March 2016, the Australian Pharmaceutical Benefits scheme listed a number of DAAs (Direct-acting antivirals) for the treatment of hepatitis C, wherein it covers majority of the drug costs. As a result of this scheme, from March to September 2016, it was estimated that 25,900 number of people underwent treatment, which represents 11% of people with HCV infection.

Key Takeaways of the Global Hepatitis C Drugs Market:

  • The global hepatitis C drugs market expected to exhibit a CAGR of 4.0% over the forecast period (2019-2027), owing to increasing launches of hepatitis C drugs.
  • Among drug type, interferon based therapies segment is expected to account for a major revenue share by 2027. Interferons (IFNs) are a group of signaling proteins made by host cells in response to the presence of several viruses. For instance, Roferon A (Interferon alfa-2a, recombinant) is used in the treatment of viral infections of the liver (chronic hepatitis C).
  • Major players operating in the global hepatitis C drugs market include Abbvie Inc., Gilead sciences, Inc., BRISTOL-MYERS Squibb Company., F Hoffmann-la Roche Ltd, Merck & co., Inc., Johnson & Johnson, Natco Pharma Limited, and Kadmon holdings, Inc.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us: